MedTrace Logo

Hidradenitis Suppurativa Study of Izokibep

NCT05905783 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2025-10-15

Study results available
· View outcomes & findings →

Summary

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.

Conditions

Interventions

DRUG

Placebo

Solution for injection

DRUG

Izokibep

Solution for injection

Sponsors & Collaborators

  • ACELYRIN Inc.

    lead INDUSTRY

Principal Investigators

  • Shephard Mpofu · ACELYRIN Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-22
Primary Completion
2024-07-24
Completion
2025-01-27
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Hungary
  • Japan
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05905783 on ClinicalTrials.gov